Literature DB >> 25034363

The effect of immune microenvironment on the progression and prognosis of colorectal cancer.

Jinxiang Chen1, Zihua Chen.   

Abstract

Cancer cells may escape from host immune responses through active suppression of the immune response, but the detailed mechanisms in colorectal cancer remain to be elucidated. In this study, 108 colorectal tumor samples and their peritumoral tissues were collected for immunohistochemistry of infiltrating lymphocytes. Th1 and Tregs cells were determined by the positive expression of T-bet and FOXP3 proteins, respectively. The Tr1 cells were identified by CD49b and LAG-3 protein expression. IL-17-positive cells were identified by IL-17 expression. Results showed that the percentage of T-bet-positive cells was significantly decreased, while the percentages of IL-17-, FOXP3-, CD49b-, and LAG-3-positive cells were significantly increased in tumor tissues compared to that in peritumoral tissues. The ratio of IL-17-, FOXP3-, CD49b-, and LAG3-positive cells to T-bet-positive cells was significantly higher in tumor tissues than in peritumoral tissues. The percentage of infiltrating IL-17-positive cells in tumor tissues was negatively associated with lymph metastasis, invasion, and TNM stage. The percentage of CD49b- and LAG-3-positive cells was positively associated with differentiation, lymph metastasis, invasion, TNM, and Duke stage of colorectal cancer. The percentage of positive Th17 and Tr1 cells is a marker for poor prognosis in patients with CRC. In conclusion, decreased composition of regulative Th1 cells and increased composition of FOXP(+) Tregs-, CD49b(+)/LAG-3(+) Tr1-, and IL-17-positive cells in tumor tissues may be associated with the progression of colorectal cancer. The high percentage of IL-17- and Tr1-positive cells in tumor tissues is a predictive marker for poor prognosis of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25034363     DOI: 10.1007/s12032-014-0082-9

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  29 in total

Review 1.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

2.  Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.

Authors:  Pierpaolo Correale; Maria Saveria Rotundo; Maria Teresa Del Vecchio; Cinzia Remondo; Cristina Migali; Chiara Ginanneschi; Kwong Y Tsang; Antonella Licchetta; Susanna Mannucci; Lucia Loiacono; Pierfrancesco Tassone; Guido Francini; Pierosandro Tagliaferri
Journal:  J Immunother       Date:  2010-05       Impact factor: 4.456

3.  Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells.

Authors:  Nicola Gagliani; Chiara F Magnani; Samuel Huber; Monica E Gianolini; Mauro Pala; Paula Licona-Limon; Binggege Guo; De'Broski R Herbert; Alessandro Bulfone; Filippo Trentini; Clelia Di Serio; Rosa Bacchetta; Marco Andreani; Leonie Brockmann; Silvia Gregori; Richard A Flavell; Maria-Grazia Roncarolo
Journal:  Nat Med       Date:  2013-04-28       Impact factor: 53.440

Review 4.  Regulatory T cells in gastrointestinal tumors.

Authors:  Sukanya Raghavan; Marianne Quiding-Järbrink
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2011-08       Impact factor: 3.869

5.  Human T regulatory cells can use the perforin pathway to cause autologous target cell death.

Authors:  William J Grossman; James W Verbsky; Winfried Barchet; Marco Colonna; John P Atkinson; Timothy J Ley
Journal:  Immunity       Date:  2004-10       Impact factor: 31.745

6.  Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells.

Authors:  Mindi R Walker; Deborah J Kasprowicz; Vivian H Gersuk; Angele Benard; Megan Van Landeghen; Jane H Buckner; Steven F Ziegler
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

Review 7.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

8.  Differential expression and prognostic role of selected genes in colorectal cancer patients.

Authors:  Pavel Pitule; Ondrej Vycital; Jan Bruha; Petr Novak; Petr Hosek; Vladislav Treska; Ivona Hlavata; Pavel Soucek; Milena Kralickova; Vaclav Liska
Journal:  Anticancer Res       Date:  2013-11       Impact factor: 2.480

9.  The changes of Th17 cells and the related cytokines in the progression of human colorectal cancers.

Authors:  Jiansheng Wang; Kaiyu Xu; Jing Wu; Chenghua Luo; Yuchen Li; Xuebin Wu; Hong Gao; Guosheng Feng; Bao-Zhu Yuan
Journal:  BMC Cancer       Date:  2012-09-21       Impact factor: 4.430

10.  Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells.

Authors:  Chiara F Magnani; Giada Alberigo; Rosa Bacchetta; Giorgia Serafini; Marco Andreani; Maria Grazia Roncarolo; Silvia Gregori
Journal:  Eur J Immunol       Date:  2011-05-13       Impact factor: 5.532

View more
  38 in total

1.  Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome.

Authors:  Juan C Mira; Lori F Gentile; Brittany J Mathias; Philip A Efron; Scott C Brakenridge; Alicia M Mohr; Frederick A Moore; Lyle L Moldawer
Journal:  Crit Care Med       Date:  2017-02       Impact factor: 7.598

Review 2.  Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.

Authors:  Rachel E O'Neill; Xuefang Cao
Journal:  Adv Cancer Res       Date:  2019-04-17       Impact factor: 6.242

Review 3.  Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor.

Authors:  Elisa Ruffo; Richard C Wu; Tullia C Bruno; Creg J Workman; Dario A A Vignali
Journal:  Semin Immunol       Date:  2019-04       Impact factor: 11.130

Review 4.  The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review.

Authors:  Simone Punt; Jessica M Langenhoff; H Putter; Gert Jan Fleuren; Arko Gorter; Ekaterina S Jordanova
Journal:  Oncoimmunology       Date:  2015-03-06       Impact factor: 8.110

Review 5.  Immunotherapy in colorectal cancer: for the select few or all?

Authors:  Sukeshi Patel Arora; Devalingam Mahalingam
Journal:  J Gastrointest Oncol       Date:  2018-02

6.  LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma.

Authors:  Wei-Wei Deng; Liang Mao; Guang-Tao Yu; Lin-Lin Bu; Si-Rui Ma; Bing Liu; J Silvio Gutkind; Ashok B Kulkarni; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  Oncoimmunology       Date:  2016-10-07       Impact factor: 8.110

Review 7.  LAG3 (CD223) as a cancer immunotherapy target.

Authors:  Lawrence P Andrews; Ariel E Marciscano; Charles G Drake; Dario A A Vignali
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 8.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

Authors:  Ana C Anderson; Nicole Joller; Vijay K Kuchroo
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

9.  Relationship between polymorphisms of the lipid metabolism-related gene PLA2G16 and risk of colorectal cancer in the Chinese population.

Authors:  Xiao-Nv Xie; Jing Yu; Li-Hua Zhang; Zhi-Ying Luo; Dong-Sheng Ouyang; Ling-Jie Zheng; Chun-Yang Wang; Li Yang; Ling Chen; Zhi-Rong Tan
Journal:  Funct Integr Genomics       Date:  2018-10-20       Impact factor: 3.410

10.  Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives.

Authors:  Timothy J Zumwalt; Ajay Goel
Journal:  Curr Colorectal Cancer Rep       Date:  2015-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.